By Bryan Koenig (October 18, 2021, 9:06 PM EDT) — The trade group for the generic-drug industry has joined Impax Laboratories in asking the U.S. Supreme Court to overturn a Fifth Circuit decision upholding the Federal Trade Commission’s claim that an agreement the generic maker cut with Endo Pharmaceuticals Inc. over the opioid pain medication Opana ER ran afoul of antitrust laws.
The Association for Accessible Medicines, the trade lobby for manufacturers of generic-drugs as well as biosimilar versions of large molecule biologic therapies, filed an amicus brief Friday backing Impax Laboratories’ bid for high court intervention. In addition to attacking the company’s Fifth Circuit loss on the merits, AAM also argued that…
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!
The concept of veto power in legislative processes holds a significant place in democratic governance, and India, as the world’s largest democracy, has a complex and nuanced legislative structure.
